

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use several sheets if necessary)
(37 CFR 1.98(b))

ATTY. DOCKET NO. 9655	SERIAL NO.
APPLICANT Josee GOLAY et al.	
FILING DATE December 11, 2001	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
W3S	AL	WO 97/45142	12/97	International WO	—	—	yes
W3S	AM	WO 98/42824	10/98	International WO	—	—	yes
	AN						
	AO						
	AP						

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

W3S	AR	by P. MC LAUGHLIN et al., "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program", <u>JOURNAL OF CLINICAL ONCOLOGY</u> , vol. 16, August 1998, Abstract.
W3S	AS	by S. VERZELETTI et al., "Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: Clinical follow-up and improved new vectors", <u>HUMAN GENE THERAPY</u> , vol. 9, no. 15, October 1998, pages 2243-2251.
W3S	AT	by Martino INTRONA et al., "Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies", <u>HUMAN GENE THERAPY</u> , vol. 11, no. 4, March 2000, pages 611-620.

EXAMINER

DATE CONSIDERED

6/22/2005

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.